Works by Stalbovskaya, Viktoriya

Results: 7

Estimands for overall survival in clinical trials with treatment switching in oncology.

Published in:

Pharmaceutical Statistics, 2022, v. 21, n. 1, p. 150, doi. 10.1002/pst.2158

By:

Manitz, Juliane;
Kan‐Dobrosky, Natalia;
Buchner, Hannes;
Casadebaig, Marie‐Laure;
Degtyarev, Evgeny;
Dey, Jyotirmoy;
Haddad, Vincent;
Jie, Fei;
Martin, Emily;
Mo, Mindy;
Rufibach, Kaspar;
Shentu, Yue;
Stalbovskaya, Viktoriya;
Tang, Rui;
Yung, Godwin;
Zhou, Jiangxiu

Publication type:

Article

Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.

Published in:

Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 324, doi. 10.1002/pst.2079

By:

Casey, Michelle;
Degtyarev, Evgeny;
Lechuga, María José;
Aimone, Paola;
Ravaud, Alain;
Motzer, Robert J.;
Liu, Feng;
Stalbovskaya, Viktoriya;
Tang, Rui;
Butler, Emily;
Sailer, Oliver;
Halabi, Susan;
George, Daniel

Publication type:

Article

Response to comments on "Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects" by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18:287‐303, DOI: 10.1002/pst.1923

Published in:

Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 736, doi. 10.1002/pst.2021

By:

Jiménez, José L.;
Stalbovskaya, Viktoriya;
Jones, Byron

Publication type:

Article

Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 287, doi. 10.1002/pst.1923

By:

Jiménez, José L.;
Stalbovskaya, Viktoriya;
Jones, Byron

Publication type:

Article

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Published in:

British Journal of Haematology, 2016, v. 173, n. 6, p. 938, doi. 10.1111/bjh.13644

By:

Guglielmelli, Paola;
Rotunno, Giada;
Bogani, Costanza;
Mannarelli, Carmela;
Giunti, Laura;
Provenzano, Aldesia;
Giglio, Sabrina;
Squires, Matthew;
Stalbovskaya, Viktoriya;
Gopalakrishna, Prashanth;
Vannucchi, Alessandro M.

Publication type:

Article

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

Published in:

Experimental Hematology & Oncology, 2015, v. 4, n. 1, p. 1, doi. 10.1186/s40164-015-0021-2

By:

McMullin, Mary Frances;
Harrison, Claire N.;
Niederwieser, Dietger;
Demuynck, Hilde;
Jäkel, Nadja;
Gopalakrishna, Prashanth;
McQuitty, Mari;
Stalbovskaya, Viktoriya;
Recher, Christian;
Theunissen, Koen;
Gisslinger, Heinz;
Kiladjian, Jean-Jacques;
Al-Ali, Haifa-Kathrin

Publication type:

Article

Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

Published in:

2016

By:

Al-Ali, Haifa Kathrin;
Stalbovskaya, Viktoriya;
Gopalakrishna, Prashanth;
Perez-Ronco, Julian;
Foltz, Lynda

Publication type:

Letter to the Editor